Vairavan Latha 4
4 · Arcutis Biotherapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Arcutis (ARQT) CFO Vairavan Latha Sells 1,320 Shares
What Happened
Vairavan Latha, Chief Financial Officer of Arcutis Biotherapeutics (ARQT), sold 1,320 shares in an open-market transaction on February 2, 2026. The weighted average sale price was $25.50 per share for total proceeds of $33,658. The filing states the sale was to satisfy tax withholding obligations arising from the vesting of previously granted RSUs.
Key Details
- Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (appears timely).
- Transaction type: Sale (open market) to cover tax withholding related to RSU vesting (footnote F1).
- Shares sold: 1,320; weighted average price reported $25.50; proceeds $33,658.
- Price range: shares sold in multiple transactions at prices from $24.745 to $25.68 (footnote F2). The reporting person will provide per-price breakdown on request.
- RSU details (per footnote F1): RSUs were granted 01/12/2024; 25% vest annually on Feb 1 beginning Feb 1, 2025, subject to continued service.
- Shares owned after transaction: not disclosed in the provided filing.
Context
This was a "sell-to-cover" transaction to meet tax withholding on vested RSUs, which is a common, administrative reason for insider sales and not necessarily a signal about the insider’s view of the company. The filer has offered to provide detailed per-trade pricing if requested by the SEC, the company, or a security holder.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-02$25.50/sh−1,320$33,658→ 63,607 total
Footnotes (2)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.